Financial

Mylan to invest $1 billion in India on capex in 6 years

Multinational drug company Myaln has said it will invest $1 billion in the next 5-6 years on capex in India, given the importance of the country's position in world pharma supply-chain, and pitched for the government incentivising research and development activities.
Read more : https://www.livemint.com/companies/news/mylan-to-invest-1-billion-in-india-on-capex-in-6-years-11569755400013.html

Indian pharma market sees growth of 11.5% in Q2FY20

Led by seasonal factors and a stable growth of chronic segment, Indian pharmaceutical market (IPM) expanded 11.5 percent for the quarter ended September 30, according to market research firm AIOCD-AWACS.
Read more : https://www.moneycontrol.com/news/business/indian-pharma-market-sees-growth-of-11-5-in-q2fy20-4515591.html

Pharma R&D spend to stay low this year

Research and development (R&D) spends of Indian pharma companies have been coming down since FY17 and are expected to remain low in FY20 as well due to challenging market conditions in the US.
Read more : https://asianage.com/business/in-other-news/081019/pharma-rd-spend-to-stay-low-this-year.html

In a departure from the usual practice, not all essential drugs will find their prices capped. The Standing National Committee on Medicines, which has been tasked with preparing the shortlist, will meet stakeholders on November 4 to consider their views before the National List of Essential Medicines (NLEM) 2019 is updated and finalised.
Read more : http://economictimes.indiatimes.com/articleshow/71798680.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

The Indian pharma market is valued at $20 billion and has been growing at 10-12 per cent. Continuation of current growth trends could propel the market to $35 billion by 2025, the report noted.
Read more : http://economictimes.indiatimes.com/articleshow/71650516.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

The Veeda Newsletter